Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After Prolonged Share Price Weakness

How BioMarin Pharmaceutical’s Recent Moves Set Up a Closer Look at Value

Before we get into the numbers, if you are wondering whether BioMarin Pharmaceutical’s current share price fairly reflects its long term potential, it helps to first step back and see what the market has been doing with the stock lately.

BioMarin’s share price closed at US$58.51 most recently, with returns of 4.3% decline over the past week, 3.0% decline over the past month, a 1.6% decline year to date, and a 15.7% decline over the last year. This adds to a 36.2% decline over three years and 25.2% decline over five years, which gives important context for any valuation work.

While there has not been a single headline event mentioned here that clearly explains these moves, news flow around companies like BioMarin typically includes regulatory updates, product pipeline developments, and partnership announcements. All of these can affect how investors think about risk and long term prospects. Keeping that in mind can help you separate short term sentiment from what the business might be worth over time.

Against this backdrop, BioMarin currently scores 2 out of 6 on our valuation checks. This means it screens as undervalued on two of six measures, which you can see in detail in our valuation score of 2. Next we will look at how different valuation approaches line up on the stock before touching on an even more complete way to think about value at the end of the article.

BioMarin Pharmaceutical scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: BioMarin Pharmaceutical Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of a company’s future cash flows and discounts them back to today’s dollars. It aims to show what the business might be worth based on those projected cash streams.

For BioMarin Pharmaceutical, the 2 Stage Free Cash Flow to Equity model starts with last twelve month free cash flow of about $711.95 million. Analysts have provided forecasts up to 2030, with projected free cash flow of $1,581 million in that year. Beyond the explicit analyst period, Simply Wall St extrapolates additional annual cash flow figures to complete the 10 year projection path in this model.

Using these projections, the DCF output suggests an estimated intrinsic value of roughly $196.11 per share, compared with the recent share price of $58.51. That gap implies the stock is about 70.2% below this particular cash flow based estimate of value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests BioMarin Pharmaceutical is undervalued by 70.2%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for BioMarin Pharmaceutical.

Approach 2: BioMarin Pharmaceutical Price vs Earnings

For a company that is generating earnings, the P/E ratio is a straightforward way to see how much investors are paying for each dollar of profit. It is popular because it links the share price directly to the bottom line, which is usually what ultimately matters to equity holders.

What counts as a “normal” P/E depends a lot on how fast earnings are expected to grow and how risky those earnings are. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher uncertainty can point to a lower one.

BioMarin Pharmaceutical currently trades on a P/E of 32.25x, compared with the Biotechs industry average of about 20.88x and a peer average of 19.73x. Simply Wall St’s Fair Ratio for BioMarin is 25.73x, which is its proprietary estimate of what a reasonable P/E might be given the company’s earnings profile, industry, profit margins, market cap and specific risks. This Fair Ratio can be more tailored than a simple industry or peer comparison because it aims to reflect the company’s own characteristics rather than broad group averages. On this measure, BioMarin’s current P/E sits above the Fair Ratio, which points to the shares being priced higher than that model suggests.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your BioMarin Pharmaceutical Narrative

Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St’s Community page you can use Narratives, where you choose the story you believe about BioMarin Pharmaceutical, link that story to specific forecasts for revenue, earnings and margins, and see a Fair Value that updates automatically when new news or results arrive. You can then compare it with the current price to help you decide what to do, whether that is a bullish view with a Fair Value around US$120, a more neutral view closer to US$88.65, or a cautious view nearer US$60, each reflecting a different outlook on the same company.

Do you think there's more to the story for BioMarin Pharmaceutical? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com